Anzeige
Mehr »
Freitag, 06.03.2026 - Börsentäglich über 12.000 News
"Unbegrenzte Munition?" - Ohne diesen kritischen Rohstoff bleibt es wohl nur ein Versprechen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
366 Leser
Artikel bewerten:
(1)

MYONEX CLOSES CREAPHARM ACQUISITION EXPANDING GLOBAL SERVICES

HORSHAM, Pa., May 2, 2024 /PRNewswire/ -- Myonex has completed the previously announced acquisition of CREAPHARM's pharmaceutical services business. This transaction combines capabilities and flexibility to serve pharmaceutical and biotech companies in both clinical and commercial stages, including companies managing Advanced Therapies. Creapharm's clinical packaging and distribution services, commercial packaging operations and bioservices will now be known as Creapharm, a Myonex company.

Myonex is a leading global clinical trial supply company based in Horsham, PA. Learn more at Myonex.com.

"We are thrilled to have completed the acquisition of Creapharm, a milestone that expands our services and enhances our capabilities for clients and the industry. Together, we are poised to meet the dynamic needs of our clients with agility, flexibility, and reliability," stated James Lovett, CEO of Myonex.

"We are excited to welcome Eric Placet, the visionary founder and former CEO of CREAPHARM, to the Myonex Board of Directors. His decision to reinvest in the company is a testament to our shared commitment to excellence and innovation. Additionally, we are pleased to announce the appointment of Carla Da Costa as our Chief Operating Officer, further strengthening our executive team as we continue to drive growth and deliver exceptional value to our clients," stated Mike Cohen, Executive Chairman, Myonex. Edouard Placet will continue in his role as Strategic Development Director of Myonex.

Myonex was advised by McDermott, Will & Emery in France along with Troutman Pepper in the United States as its legal advisors, and Crosstree Capital Partners as its financial advisors, in its acquisition of Creapharm. Creapharm was advised in France on the M&A legal part by ARST Avocats and on the fiscal and corporate legal part by Nomodos. Additionally, Nelson Mullins acted as US legal advisor and Rothschild&Co as financial advisor.

About Myonex

Myonex is a leading global complete clinical trial supply company offering tailored solutions in central and local drug sourcing, packaging, labeling, and ancillary and equipment supply to support each trial's specific requirements and complexities. With locations in the US, Germany, & UK, we partner with pharmaceutical and biotechnology companies, contract research organizations (CROs), and other clinical trial service providers seeking a flexible, comprehensive solution for their trial supply needs. Learn more at www.myonex.com

About Creapharm
With decades of experience in global clinical trial supply management, Creapharm supports Pharma and Biotech key players with customized solutions. Creapharm has a strong expertise in cold-chain management and recently developed ultra-cold solutions to handle biologicals and ATMP supply chain management. For marketed health products, Creapharm offers expert commercial packaging services to pharmaceutical and food supplement industries. Learn more at www.creapharm-pharma.com.

CONTACT:
Maryanne Walsh
(+1) 267-307-0876

Logo - https://mma.prnewswire.com/media/2381955/4683277/MYONEX_RGB__1_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/myonex-closes-creapharm-acquisition-expanding-global-services-302134181.html

© 2024 PR Newswire
Tech-Aktien schwanken – 3 Versorger mit Rückenwind
Die Stimmung an den Märkten hat sich grundlegend gedreht. Während Tech- und KI-Werte zunehmend mit Volatilität und Bewertungsrisiken kämpfen, erleben klassische Versorger ein unerwartetes Comeback. Laut IEA und EIA steigt der globale Strombedarf strukturell weiter, nicht nur wegen E-Mobilität und Wärmepumpen, sondern vor allem durch energiehungrige KI-Rechenzentren. Energie wird damit zur zentralen Infrastruktur des digitalen Zeitalters.

Gleichzeitig rücken in unsicheren Marktphasen stabile Cashflows, solide Bilanzen und regulierte Renditen wieder stärker in den Fokus. Genau hier spielen Versorger ihre Stärken aus: berechenbare Erträge, robuste Nachfrage und hohe Dividenden – Qualitäten, die vielen Wachstumswerten aktuell fehlen.

Nach Jahren im Schatten der Tech-Rallye steigt nun das Interesse an Unternehmen, die Stabilität mit langfristigen Wachstumsthemen wie Netzausbau, Dekarbonisierung und erneuerbaren Energien verbinden.

Im aktuellen Spezialreport stellen wir drei Versorger vor, die defensive Stärke mit attraktivem Potenzial kombinieren.

Jetzt den kostenlosen Report sichern – bevor die nächste Versorgerwelle Fahrt aufnimmt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.